Replies to post #549576 on $Stock*Shop*Charts*News*Option$

[dDT]

SHPG Shire Q3 earnings up 72%, guidance raised

Shire plc (NASDAQ:SHPG) Q3 results ($M): Revenues: 1,597.1 (+31.7%); COGS: 254.3 (+40.9%); R&D Expense: 228.6 (+1.1%); SG&A Expense: 522.9 (+31.9%); Operating Income: 572.0 (+49.4%); Net Income: 479.7 (+72.4%); Earnings/ADS: 2.427 (+65.8%); Quick Assets: 467.7 (-79.1%); CF Ops: 593.4 (+36.8%).
Product Sales: Vyvanse: 354.9 (+18.6%); Lialda/Mezavant: 176.6 (+24.5%); Elaprase: 168.8 (+30.8%); Cinryze: 145.1; Replagal: 135.9 (+25.3%); Firazyr: 98.4 (+57.2%).
2014 Guidance: Product sales growth: low 20% range from high teens range; non-GAAP earnings per ADS: high 30% range from low-to-mid 30% range; Royalties and other revenues: 0 - 5% lower than 2013; non-GAAP gross margin: ~1% lower than 2013; R&D plus SG&A growth: 2 - 4% compared to 2013.
Q4 Guidance: Product sales growth: lower than Q3.

Shares up +4.52% premarket